Claims for Patent: 7,959,945
✉ Email this page to a colleague
Summary for Patent: 7,959,945
| Title: | Dispersible bosentan tablet |
| Abstract: | The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2- -yl)-pyrimidin-4-yl]-benzenesulfonamide. |
| Inventor(s): | Holman; Lovelace (Arlesheim, CH), Trenktrog; Timm (Binningen, CH) |
| Assignee: | Actelion Pharmaceuticals Ltd. (Allschwil, CH) |
| Application Number: | 11/914,652 |
| Patent Claims: |
1. A dispersible tablet consisting of 33.045 mg of compound I of the formula ##STR00002## as monohydrate; 116.265 mg of microcrystalline cellulose; I 01.5 mg of
dicalcium phosphate; 11.6 mg of croscarmellose sodium; 2.9 mg of colloidal silicon dioxide; 7.0 mg of tartaric acid; 9.0 mg of flavoring agent; 3.7 mg of aspartame; 1.8 mg of acesulfame potassium; and 3.19 mg of magnesium stearate.
2. A dispersible tablet consisting of 33.045 mg of compound I of the formula ##STR00003## as monohydrate; 135.2 mg of microcrystalline cellulose; 70.0 mg of dicalcium phosphate; 11.2 mg of croscarmellose sodium; 2.8 mg of colloidal silicon dioxide; 6.25 mg of tartaric acid; 9.0 mg of flavoring agent; 3.7 mg of aspartame; 1.8 mg of acesulfame potassium; 1.4 mg of magnesium stearate, and 5.6 mg of glyceryl dibehenate. 3. A dispersible tablet consisting of 33.045 mg of compound I of the formula ##STR00004## as monohydrate; 79.765 mg of microcrystalline cellulose; 63.0 mg of dicalcium phosphate; 8.4 mg of croscarmellose sodium; 2.1 mg of colloidal silicon dioxide; 6.25 mg of tartaric acid; 9.0 mg of flavoring agent; 3.7 mg of aspartame; 1.8 mg of acesulfame potassium; and 2.94 mg of magnesium stearate. |
